Clinical Trial

Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 27, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received antihypertensive drug treatment
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-28
Trial Details
NCT Number NCT07469800
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Overweight, Obesity, Hypertensive
Enrollment 336 participants
Start Date 2026-04-23
Primary Completion 2026-08-01 (estimated)
Study Completion 2027-04-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-27